Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR (A1SN34) Stock Price & Analysis

A1SN34 Stock Chart & Stats

$88.11$0.00(0.00%)

At close: Oct 30

Day’s Range: $88.11 - $91.62
52-Week Range: $26.43 - $99.76
Previous Close: $88.11
Volume: N/A
Average Volume (3M): 52
Market Cap: BRL 85.22B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -0.14
Next Earnings: Nov 11, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR News

Ascendis Pharma announces new data from PaTH Forward, PaTHway trials

Ascendis Pharma (ASND) announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon PTH for up to five years in

1w agoASND

Ascendis Pharma initiated with a Hold at Canaccord

Canaccord initiated coverage of Ascendis Pharma (ASND) with a Hold rating and $268 price target The company is executing very well with its rare endocrinology franchise that includes three commercial

1w agoASND

Ascendis Pharma price target lowered to $330 from $360 at Citi

Citi analyst Eric Joseph lowered the firm’s price target on Ascendis Pharma (ASND) to $330 from $360 and keeps a Buy rating on the shares. The firm expects the company’s

1w agoASND

Ascendis Pharma: Buy Rating Reiterated as YUVIWEL Outperformance Potential Supports Unchanged $344 Price Target

H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on ASND stock, giving a Buy rating on October 16. Mitchell Kapoor has given his Buy rating due to a

2w agoASND

Ascendis gets CHMP opinion recommending marketing authorization for TransCon CNP

Ascendis Pharma (ASND) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted an opinion recommending marketing authorization for

2w agoASND

Ascendis Pharma assumed with a Buy at UBS

UBS assumed coverage of Ascendis Pharma (ASND) with a Buy rating with a price target of $269, down from $307. The company’s key drug, Yorvipath for chronic hypoparathyroidism, is on

2w agoASND

Ascendis Pharma: Strong Commercial Momentum Across Yorvipath, Yuviwel, and Skytrofa Drives Buy Rating with Unchanged $304 Price Target

Tazeen Ahmad, an analyst from Bank of America Securities, reiterated the Buy rating on Ascendis Pharma. The associated price target remains the same with $304.00. Tazeen Ahmad has given his

3w agoASND

Ascendis Pharma: Buy Rating Reaffirmed as Analyst Maintains $344 12‑Month Price Target Amid Strategic Upside From TransCon Assets

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Ascendis Pharma and keeping the price target at $344.00. Mitchell Kapoor has given his Buy rating due to a

1M agoASND

Ascendis Pharma falls -12.8%

Ascendis Pharma (ASND) is down -12.8%, or -$33.92 to $231.00. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks

1M agoASND

Ascendis Pharma: Buy Rating Reaffirmed as Durable Franchise, New Launches, and $400M Buyback Support Unchanged $319 Price Target

In a report released yesterday, David Lebowitz from BMO Capital maintained a Buy rating on Ascendis Pharma, with a price target of $319.00. David Lebowitz has given his Buy rating

1M agoASND

Ascendis Pharma falls -12.1%

Ascendis Pharma (ASND) is down -12.1%, or -$32.14 to $232.78. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks

1M agoASND

Ulta Beauty, Etsy upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

1M agoAGL CLS

Ascendis Pharma downgraded to Outperform from Strong Buy at Raymond James

Raymond James downgraded Ascendis Pharma (ASND) to Outperform from Strong Buy with an unchanged price target of $287 after the company announced it will regain the rights on the TransCon

1M agoASND

Ascendis Pharma to regain rights to TransCon technology-based products

Ascendis Pharma (ASND) announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows termination of

1M agoNVO ASND

A1SN34 FAQ

What was Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR’s price range in the past 12 months?

Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR lowest stock price was $26.43 and its highest was $99.76 in the past 12 months.

What is Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR’s market cap?

Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR’s market cap is R$85.22B.

When is Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR pay dividends?

Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR does not currently pay dividends.

What is Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR’s EPS estimate?

Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR have?

Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR has 62,376,846 shares outstanding.

Which hedge fund is a major shareholder of Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR?

Currently, no hedge funds are holding shares in BR:A1SN34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR (A1SN34) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	13	2	7
Technical Analysis	2	2	6
Moving Averages	11	0	1

Technical Analysis >

Similar Stocks

Stocks similar to BR:A1SN34
Company	Price & Change	Follow
BR:B1AX34Baxter International Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 Sh
BR:B1MR34Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
BR:J2AZ34Jazz Pharmaceuticals PLC Unsponsored BDR
BR:N1BI34Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh
BR:P2OD34Insulet Corp Shs Unsponsored Brazilian Depositary Receipt Repr 0.03333333 Sh

Compare BR:A1SN34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

A1SN34 Stock Chart & Stats

Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR News

Ascendis Pharma announces new data from PaTH Forward, PaTHway trials

Ascendis Pharma initiated with a Hold at Canaccord

Ascendis Pharma price target lowered to $330 from $360 at Citi

Ascendis Pharma: Buy Rating Reiterated as YUVIWEL Outperformance Potential Supports Unchanged $344 Price Target

Ascendis gets CHMP opinion recommending marketing authorization for TransCon CNP

Ascendis Pharma assumed with a Buy at UBS

Ascendis Pharma: Strong Commercial Momentum Across Yorvipath, Yuviwel, and Skytrofa Drives Buy Rating with Unchanged $304 Price Target

Ascendis Pharma: Buy Rating Reaffirmed as Analyst Maintains $344 12‑Month Price Target Amid Strategic Upside From TransCon Assets

Ascendis Pharma falls -12.8%

Ascendis Pharma: Buy Rating Reaffirmed as Durable Franchise, New Launches, and $400M Buyback Support Unchanged $319 Price Target

Ascendis Pharma falls -12.1%

Ulta Beauty, Etsy upgraded: Wall Street’s top analyst calls

Ascendis Pharma downgraded to Outperform from Strong Buy at Raymond James

Ascendis Pharma to regain rights to TransCon technology-based products

A1SN34 FAQ

Ascendis Pharma ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR (A1SN34) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium